Close Banner
Section Free  - Quick Takes

05. Effect of Anxiolytic Drug Silexan on Sleep – A Narrative Review

Published on March 1, 2023 Certification expiration date: March 1, 2026

James Phelps, M.D.

Research Editor - Psychopharmacology Institute

Key Points

  • Looking for an alternative to benzodiazepines? Here’s a review that finds extract of lavender (Silexan in Germany; “Calm Aid” over the counter in the United States) to have efficacy in the treatment of insomnia, parallelling previous reviews showing efficacy for anxiety.
  • The catch? All the studies, and these reviews, appear to have extensive support from the German manufacturer, including authorship. 
  • But does it matter? Placebos can be quite effective in anxiety and insomnia. With the available randomized trial evidence, recommending extract of lavender does not violate ethical standards.

Free Downloads for Offline Access

  • Free Download Audio File (MP3)

Text version

This is going to sound too good to be true. How would you like a medication that works as well as a benzodiazepine for anxiety but causes no dependence or withdrawal? It has no side effects except mild nausea in 3% of users and no known long-term risks. It has no interactions with any of the P450 cytochromes and no other known drug interactions. It’s been around for over a decade in Germany, where it’s widely used. And now, you can get it in the United States and perhaps in other countries without a prescription. In my local grocery store, it costs $17 for a month’s supply of the larger, more effective dose and half that for a dose that’s certainly an excellent placebo, if not better. And now comes a review that suggests that this medication works well for insomnia too. Do I have your attention?

Hi! Jim Phelps here for the Psychopharmacology Institute. It’s not really a medication after all. It’s extract of lavender. In Germany, the pill version is called Silexan. In the United States, the same compound in the same concentrations is available over the counter as CalmAid. My local supermarket carries it. But now I’m going to throw some cold water on all this enthusiasm. Here it goes: Nearly every randomized trial that I can find was conducted by researchers who received honoraria from its German manufacturer, and the most recent meta-analysis of its efficacy was funded by the company, which prepared the statistical analysis and drafted the manuscript. Basically, what we’re reading is advertisements. That doesn’t mean that it doesn’t work, but it raises some suspicions about whether it’s as good as the publications make it sound.

On the other hand, suppose it really is just an elegant placebo—cheap, apparently nearly harmless, and appealing. What doesn’t sound good about extract of lavender? As you know, placebos have very good results in the treatment of anxiety and insomnia. So, actually, I should be careful not to foster your disbelief. Indeed, I should promote it, just as do the authors of this new review, including regarding its effects on insomnia, because if you believe it’s a great approach, many of your patients will too and it will help them. Moreover, there are actually good biochemical reasons to think that extract of lavender actually is psychoactive. Like pregabalin, lavender extract also inhibits calcium channels with a net effect on glutamate and norepinephrine. According to this new review and a previous one in 2015, there are multiple reasons to believe that lavender extract really is doing something specific in the brain. But these reviews, like the randomized trials, have been authored by Dr. Siegfried Kasper along with authors in the direct employ of the manufacturer.

Well, back to the results. Lavender extract vs placebo for insomnia. In 1 study, as measured by the standard scale, the Pittsburgh Sleep Quality Index, lavender extract was associated with an 8-point drop vs a 6-point reduction with placebo. That difference was statistically significant. But clinically significant? How big is 2 points on the PSQI? Well, a small literature based on studies in sports medicine, acupuncture, and pulmonary disease suggests that a minimal clinically important difference on the PSQI is somewhere between 1.5 and 3 or 4. Suffice to say that a shift of 2 points is not huge but probably noticeable. Better, how about a head-to-head comparison with 0.5 mg of lorazepam? Reviewing the abstract of that study, it looks like it was fairly rigorous even though the second author is an employee of the Silexan manufacturer. The results in that context? Equal improvement in anxiety scores with Silexan and low-dose lorazepam 0.5 mg, including the insomnia subscore. But was the sample big enough to detect a difference? Unfortunately, the abstract doesn’t give us those numbers.

In summary, for now, we’re seeing the same results for insomnia that were seen for anxiety scores overall with extract of lavender vs placebo. If it weren’t for the direct connections to the manufacturer in these publications, we’d have good evidence for Silexan over the counter as an apparently safe alternative to benzodiazepines for anxiety and sleep. But we can definitely say that extract of lavender is at least as good as a placebo, knowing that placebos themselves can be highly effective for anxiety and sleep. It all depends on whether your patient believes the pills can help, which is determined by whether you believe they can help. And clearly, they can. Given the published data, you don’t have to worry about the ethical problems of recommending a placebo.

For more on this, a review of its efficacy for anxiety is presented by Moller et al. 2019. This review is linked here at the Psychopharmacology Institute.

Abstract

Effect of Anxiolytic Drug Silexan on Sleep – A Narrative Review

Erich Seifritz, Siegfried Kasper, Hans-Jürgen Möller, Hans-Peter Volz, Walter E Müller, Anne Eckert, Martin Hatzinger

Objectives: Silexan is an orally administered, proprietary essential oil from Lavandula angustifolia with significant anxiolytic and sleep improving properties. Here we present a narrative review that provides an overview of the available evidence of the effects of silexan on sleep.

Methods: We start with a summary of the pharmacological background and continue with presenting sleep-related results from controlled clinical trials with silexan. Then we report on a meta-analysis of item ‘insomnia’ from the Hamilton Anxiety Scale, which includes data from all randomised, placebo-controlled clinical trials with silexan in which the scale was administered. Finally, we summarise the results of a mediation analysis that was performed to elucidate the pathway of the effect of silexan on sleep.

Results: In randomised, placebo-controlled trials in patients suffering from anxiety disorders silexan had a significant anxiolytic effect and improved sleep along with recovery from anxiety. Mediation analysis demonstrates that more than 98% of the effect of silexan on sleep was mediated by its anxiolytic effect while the direct effect on sleep was marginal.

Conclusions: Silexan improves sleep as a result of its anxiolytic effect.

Keywords: Silexan; anxiety; lavender oil; narrative review; sleep.

Free Files
Success!
Check your inbox, we sent you all the materials there.

Reference

Seifritz, E., Kasper, S., Möller, H. J., Volz, H. P., Müller, W. E., Eckert, A., & Hatzinger, M. (2022). Effect of anxiolytic drug silexan on sleep – a narrative review. The World Journal of Biological Psychiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry, 23(7), 493–500.

  • Möller, H. J., Volz, H. P., Dienel, A., Schläfke, S., & Kasper, S. (2019). Efficacy of silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials. European Archives of Psychiatry and Clinical Neuroscience, 269(2), 183-193.
  • Kasper, S., Müller, W. E., Volz, H. P., Möller, H. J., Koch, E., & Dienel, A. (2018). Silexan in anxiety disorders: Clinical data and pharmacological background. The World Journal of Biological Psychiatry, 19(6), 412-420.

Learning Objectives:

  1. Examine whether baseline cognitive function is a predictor of illness course in first-episode schizophrenia. 
  2. Evaluate the research basis for the “3 strikes rule” of antidepressant treatment for recurrent depression.
  3. Discuss the evidence base regarding the efficacy of mirtazapine as an adjunctive agent for the management of clozapine-resistant schizophrenia.
  4. Examine whether C-reactive protein can be a clinically useful predictor of antidepressant response.
  5. Evaluate the efficacy of extract of lavender for the treatment of insomnia.

Original Release Date: March 1, 2023

Review and Re-release Date: March 1, 2024

Expiration Date: March 1, 2026

Expert: James Phelps, M.D.

Medical Editor: Melissa Mariano, M.D.

Relevant Financial Disclosures: 

James R Phelps declares the following interests:

- McGraw-Hill:  Royalties

- W.W. Norton & Co.:  Royalties

All of the relevant financial relationships listed above have been mitigated by Medical Academy and the Psychopharmacology Institute.

Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

  1. View the required educational content provided on this course page.

  2. Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.

  3. Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Free Files
Success!
Check your inbox, we sent you all the materials there.
Continue in the website
Instant access modal

Become a Silver, Gold, Silver extended or Gold extended Member.

2025–26 Psychopharmacology CME Program

Unlock up to 155 CME Credits, including 40 SA CME Credits.